A novel method for increasing MHC presentation of oncogene derived neoantigens

Tech ID: 31833 / UC Case 2020-070-0

Invention Novelty

The invention describes a platform technology that increases MHC presentation of oncogene derived peptide neoantigens that do not normally occur in the cell. The platform has already been used to identify a method of increasing KRAS G12 D/V derived peptide presentation on MHC- I.

Value Proposition

  • The invention provides a platform to screen computationally and experimentally for a cell’s ability to present cancer neoantigens. 
  • The technology provides a strategy to enhance antigen presentation and bring intracellular oncogenes to the cell surface so that they are visible by T-cell surveillance. 
  • The technology provides a new dimension of therapeutic intervention for cancer as it expands the repertoire of epitopes targetable by small molecules and/or immunotherapy.
  • Targeting driver oncogenes is advantageous because it is cancer specific and is essential for cancer growth.


Looking for Partners

We are looking for partnerships to further develop the technology as a platform that enhances cellular presentation of various oncogenes by MHC and to develop cancer therapeutics using this approach.

Stage of Development

Proof of concept

Data Availability


Patent Status

Patent Pending


Learn About UC TechAlerts - Save Searches and receive new technology matches

Other Information


oncogene-derived neoantigen, MHC presentation, small molecule

Categorized As